CAT and steatosis: Myricetin significantly reduced HFD‐induced steatosis, TBARS levels, and lipid accumulation along with showed enhancement in SOD, glutathione peroxidase (GPx) and catalase (CAT) antioxidant enzyme activities in the liver.